Stock vs Stock Comparison

Cytokinetics, Incorporated vs Agilent Technologies, Inc.

A wins the Tale of the Tape 7–2.

CYTK
A$137.40

🏆 Tale of the Tape

27
CYTKA
-891.6%Profitability (Net Margin)18.8%
Valuation (P/E)27.3x
-44.0%Efficiency (ROIC)11.8%
3/9Health (Piotroski F)5/9
Safety (Altman Z)4.6
376.6%Growth (Rev YoY)6.7%
Risk (Sharpe 1Y)0.32
-3.16xBalance Sheet (D/E)0.89x
FCF Yield3.41%

Green = winner in each category. Higher is better except P/E (lower = cheaper).

Fundamentals

MetricCYTKA
Market Cap$38.2B
P/E Ratio27.3x
Forward P/E20.5x
P/B5.37x
Dividend Yield0.75%
Beta1.22

Quantitative Metrics

MetricCYTKA
DCF Fair Value$50.34
DCF Upside-57.1%
Piotroski F3/95/9
Altman Z4.57
Beneish M-0.21-2.46
FCF Yield3.41%
Net Debt/EBITDA0.7x
ROIC-44.0%11.8%
WACC12.1%
ROIC – WACC-0.3pp
Gross Margin-372.5%52.4%
Net Margin-891.6%18.8%
Rev Growth YoY376.6%6.7%
Sharpe (1Y)0.32
Max Drawdown 3Y
FCF Payout Ratio24%

CYTK Price

Loading chart...

A Price

Loading chart...

ETF Exposure

CYTK found in:

XBI1.42%
MDYG0.31%
SPMD0.30%
MDY0.30%
MDYV0.29%
VTWO0.23%
VBK0.23%
VFMO0.20%
VHT0.12%
VXF0.10%
VB0.10%
SPTM0.01%

A found in:

MOAT1.31%
VOT0.77%
XLV0.61%
VHT0.53%
VO0.33%
ONEV0.29%
RSP0.18%
VIG0.15%
VTV0.13%
SCHV0.12%
SPYV0.11%
IWD0.11%
VONV0.10%
ONEO0.09%
ESGV0.07%
QUS0.07%
SPLG0.07%
IVV0.07%
ITOT0.06%
SCHX0.06%
SCHB0.05%
SPY0.05%
VTI0.05%
VOO0.05%
VONE0.05%
SPTM0.05%
URTH0.04%
ACWI0.04%
DGRW0.04%

More Comparisons

Quant metrics computed from financial statements and 1,200+ trading days. Correlation is Pearson coefficient on daily log returns. Not investment advice.

CYTK vs A: Head-to-Head Analysis

Cytokinetics, Incorporated (CYTK) and Agilent Technologies, Inc. (A) represent two companies in the Healthcare sector. In our quantitative Tale of the Tape scoring, A leads 7–2 across nine fundamental and risk metrics including profitability, valuation, capital efficiency, and financial health.

In terms of capital efficiency, CYTK generates a return on invested capital (ROIC) of -44.0% compared to A's 11.8%. This suggests A is more effective at deploying capital to generate shareholder returns.

CYTK appears in 12 ETFs tracked by SecuritiesDB, while A appears in 29 ETFs. Investors holding broad-market ETFs may already have indirect exposure to both stocks.

Frequently Asked Questions

Which stock is the better investment, CYTK or A?

Our quantitative analysis compares CYTK and A across nine fundamental dimensions. A wins the Tale of the Tape 7–2. However, stock selection depends on your individual risk tolerance, time horizon, and portfolio context. These metrics are computed from SEC filings and market data — they are not investment recommendations.

Are CYTK and A correlated?

Correlation data is not yet available for this pair. Check back after both stocks have sufficient trading history.

How is the Tale of the Tape scored?

The Tale of the Tape compares both stocks across nine categories: profitability (net margin), valuation (P/E), efficiency (ROIC), health (Piotroski F-Score), safety (Altman Z-Score), growth (revenue YoY), risk (Sharpe ratio), leverage (debt-to-equity), and cash generation (FCF yield). The stock that wins more categories takes the overall score. Lower P/E and lower debt-to-equity count as wins.